Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Treating septic shock with steroids produces hyperglycemia, but patients are no better off with intensive insulin therapy than with conventional glucose control, according…
NEW YORK (Reuters Health) – In patients with middle cerebral artery occlusion, an alteplase dosage of 0.6 mg/kg IV is comparable to a 0.9 mg/kg dosage for achieving…
NEW YORK (Reuters Health) – Operative mortality after coronary artery bypass grafting (CABG) is higher in women, even after adjustment for preoperative risk factors, according to a study…
NEW YORK (Reuters Health) – It makes no difference whether internal tocodynamometry or external monitoring is used during induced or augmented labor – either way, the rate of…
NEW YORK (Reuters Health) – When paroxysmal atrial fibrillation has not responded to at least one antiarrhythmic agent, radiofrequency catheter ablation is more effective at preventing further episodes…
NEW YORK (Reuters Health) – Prompt treatment of subclinical and clinical seizures in newborns with hypoxic-ischemic encephalopathy (HIE) can potentially decrease brain injury, according to a prospective trial…
NEW YORK (Reuters Health) – High-dose atorvastatin does not protect against contrast-induced nephropathy (CIN) in patients with kidney disease, Italian researchers report. “Statins have recently been proposed for…
NEW YORK (Reuters Health) – The biomarker procalcitonin can help guide treatment of severe bacterial infections in the intensive care unit (ICU), French investigators report online in The…
NEW YORK (Reuters Health) – Endovascular treatment of intracranial aneurysms 3 mm or smaller in diameter is difficult and risky — but it’s successful in over 90% of…
NEW YORK (Reuters Health) – Giving beta-blockers within 8 hours of presentation with acute coronary syndrome (ACS) does not reduce in-hospital mortality, a meta-analysis has shown. Beta-blockers reduce…
